🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the battle against drug-resistant strains of the infection, according to scientists.

A Global Challenge

Gonorrhoea infections are on the rise worldwide, with figures suggesting in excess of 82 million infections each year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the face of growing infection rates, the spread of superbugs and the very limited therapeutic options presently on offer.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Therapies Receive Clearance

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in recent days for treating gonorrhoea. This infection can lead to major issues, including infertility. Researchers anticipate that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This medication, which is also used to treat UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This approval represents a major breakthrough in the therapy of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Results and Worldwide Availability

As per data detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which combines a dual-drug approach. The study enrolled nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have voiced hope. Having a easy-to-administer therapy like this is described as a "critical tool" for public health efforts. This is viewed as crucial to lessen the impact of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.